Global Crysvita Injection Market Growth 2023-2029

Global Crysvita Injection Market Growth 2023-2029

X-linked hypophosphatemia, or XLH, is a hereditary skeletal disease triggered by excess production of the hormone fibroblast growth factor 23. FGF23 causes phosphate urinary excretion and hinders patients' ability to produce vitamin D. CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.

LPI (LP Information)' newest research report, the “Crysvita Injection Industry Forecast” looks at past sales and reviews total world Crysvita Injection sales in 2022, providing a comprehensive analysis by region and market sector of projected Crysvita Injection sales for 2023 through 2029. With Crysvita Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Crysvita Injection industry.

This Insight Report provides a comprehensive analysis of the global Crysvita Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Crysvita Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Crysvita Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Crysvita Injection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Crysvita Injection.

The global Crysvita Injection market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Crysvita Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Crysvita Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Crysvita Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Crysvita Injection players cover Kyowa Kirin and Ultragenyx Pharmaceutical etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Crysvita Injection market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
10 mg/mL
20 mg/mL
30 mg/mL

Segmentation by application
Children
Adults

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Kyowa Kirin
Ultragenyx Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Crysvita Injection market?

What factors are driving Crysvita Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Crysvita Injection market opportunities vary by end market size?

How does Crysvita Injection break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.